• News
  • SAN DIEGO
  • BioTech

UC San Diego cancer scientist wins $3 million award

Napoleone Ferrara, M.D., Ph.D., was named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award. Ferrara is the molecular biologist credited with helping decipher how tumors grow and is now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center.

The prize is the collaborative creation of Mark Zuckerberg, founder of Facebook (Nasdaq: FB), and his wife, Priscilla Chan; Sergey Brin, co-founder of Google (Nasdaq: GOOG) and his wife, Anne Wojcicki, founder of the genetics company 23andMe; and Yuri Milner, a Russian businessman and philanthropist who established a similar prize in fundamental physics last year, when $3 million each was awarded to nine researchers.

The Breakthrough Prize honors life scientists who have ambitiously pushed the boundaries of their disciplines, taken risks and impacted lives and society.

Ferrara, who is also a distinguished professor of pathology in the UC San Diego School of Medicine’s Department of Pathology, was recognized for his work identifying the role of the human VEGF gene in promoting angiogenesis -- the formation of new blood vessels that can feed tumor growth -- and subsequent development of two major monoclonal antibody drugs: Bevacizumab (marketed as Avastin), which is used to treat multiple forms of cancer, including breast, brain and colorectal; and ranibizumab (marketed as Lucentis), which treats wet age-related macular degeneration, a leading cause of blindness in the elderly.

"Napoleone's work has profoundly advanced our basic understanding of how cancer develops and grows," said David Brenner, M.D., vice chancellor for Health Sciences and dean of the UC San Diego School of Medicine. "More importantly, he helped create brand new drugs and therapies based upon that research to effectively treat a broad range of cancers and other conditions. He continues with those efforts today, pushing himself and colleagues to find better answers to cancer."

Ferrara, 56, came to UC San Diego last year after a career at Genentech, the San Francisco-based biotechnology company where he did much of his ground-breaking work. He said that when Breakthrough Prize Foundation president Arthur D. Levinson, chairman of Apple (Nasdaq: AAPL) and a former Genentech chief executive, called to tell him he had won, he was “very much astonished. I didn’t know the award existed.”

“The thing I am most proud of,” Ferrara said, “is that we’ve advanced the understanding of basic mechanisms of cancer and we’ve been able to help people, both in fighting cancer and restoring visual acuity. It’s that kind of work that I’m continuing at Moores Cancer Center, where I’ll be able to work closely with clinicians and develop new clinical trials.”

Scott Lippman, M.D., director of the UC San Diego Moores Cancer Center, said the Breakthrough Prize justly recognizes Ferrara’s seminal research and how it “has changed therapy for cancer and eye diseases.”

“His work epitomizes our overall effort at Moores Cancer Center: high-risk, high-gain, high-impact achievement and innovation in taking basic-science discovery to the clinic and transforming cancer care.”

RELATED ARTICLES:

UCSD prof.: Pig gel reduces animal heart failure with test planned in people

UCSD bioengineering professor makes big strides with tiny sensors

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!